10.1002/ejoc.201601392
European Journal of Organic Chemistry
FULL PAPER
3.74 (CH2, t, J = 6.0 Hz, 0.8H), 6.93-6.95 (Ar, m, 0.6H), 6.96-6.99 (Ar, m,
0.8H), 7.05-7.08 (Ar, m, 1.6H), 7.11 (=CH, s, 0.6H), 7.17-7.26 (Ar, m,
3H), 7.35 (=CH, s, 0.4H), 7.43-7.49 (Ar, m, 2H), 7.53-7.57 (Ar, m, 2H),
7.68 (Ar, d, J = 8.4 Hz, 0.8H), 7.73-7.75 (Ar, m, 0.6H), 7.93-7.97 (Ar, m,
2H). 13C-NMR (CDCl3), δ (ppm): (21.37, 21.42), (26.10, 28.68), (44.41,
45.59), (111.79, 119.63), (124.33, 125.88), (126.41, 126.85), (127.31,
127.35) (2C), (128.04, 128.49) (2C), 128.61 (2C), (129.06, 129.10),
(129.28, 129.55) (2C), (129.70, 129.75), (130.59, 130.89), (132.19,
132.92), (134.87, 135.17), (136.34, 136.61), (138.15, 138.71), (140.98,
143.68), (144.11, 144.13), (191.41, 193.42). LC-MS APCI (+) [M+H]+:
404.6.
20: 1H-NMR (CDCl3), δ (ppm): 2.31 (3H, s), 3.10 (2H, t, J = 7.1 Hz), 3.28-
3.31 (2H, m), 5.51 (1H, t, J = 6.0 Hz), 7.28-7.30 (1H, m), 7.32-7.35 (2H,
m), 7.50-7.53 (2H, m), 7.59 (2H, d, J = 7.6 Hz), 7.66 (1H, d, J = 7.6 Hz).
13C-NMR (CDCl3), δ (ppm): 21.38, 34.76, 43.46, 90.77, 91.18, 126.94,
127.38, 128.12 (4C), 128.93 (4C), 130.16, 131.06, 133.98, 134.19,
137.32, 137.67, 142.06, 143.08, 177.69.
mg, 0.50 mmol) and 2-iodoanisole (5f) (0.08 mL, 0.62 mmol) were mixed
in Et3N (1.5 mL) and toluene (1.0 mL). The mixture was stirred for 6 h at
110°C. The crude product was purified through column chromatography
(neutral Al2O3, n-pentane/AcOEt 3:2), obtaining 99 mg (yield 46%) of 21f
as two conformational isomers, s-trans and s-cis, in the molar ratio 60/40.
1H-NMR (CDCl3), δ (ppm): 2.27 (CH3, s, 1.8H), 2.33 (CH3, s, 1.2H), 2.49
(CH2, t, J = 6.0 Hz, 1.2H), 2.81 (CH2, t, J = 6.0 Hz, 0.8H), 3.65-3.68 (CH2,
m, 2H), 3.88 (CH3, s, 1.8H), 3.95 (CH3, s, 1.2H), 6.86-6.87 (Ar, m, 0.6H),
6.92-6.95 (Ar, m, 1H), 6.97 (Ar, d, J = 8.4 Hz, 0.8H), 7.01-7.03 (Ar, m,
1.6H), 7.06 (Ar, t, J = 7.2 Hz, 0.6H), 7.14-7.23 (Ar, m, 2.6H), 7.27 (=CH, s,
0.6H), 7.30 (Ar, d, J = 7.8 Hz, 0.4H), 7.41 (=CH, s, 0.4H), 7.42-7.43 (Ar,
m, 0.4H), 7.45-7.48 (Ar, m, 0.6H), 7.51 (Ar, d, J = 7.8 Hz, 1.2H), 7.59 (Ar,
dd, J = 7.8, 1.6 Hz, 0.4H), 7.67-7.69 (Ar, m, 1.2H), 7.77 (Ar, dd, J = 7.8,
1.6 Hz, 0.6H). 13C-NMR (CDCl3), δ (ppm): (21.33, 21.40), (25.84, 28.60),
(44.25, 45.72), (55.68, 55.84), (111.29, 111.49), (120.32, 120.54), 122.16,
(123.79, 124.32), (125.49, 125.92), 126.70, (127.27, 127.36) (2C),
(128.96, 129.12) (2C), (129.35, 129.41), (129.55, 129.63), (130.65,
131.50), (131.18, 131.35), (132.64, 133.35), (134.69, 135.24), (136.27,
136.86), (139.46, 143.41), (143.68, 143.82), (157.97, 158.63), (191.18,
192.87). LC-MS APCI (+) [M+H]+: 434.3.
Phenyl(3-tosyl-2,3-dihydro-1H-benzo[d]azepin-4-yl)methanone (21a)
(50°C). Following the general procedure, PdCl2(PPh3)2 (17.5 mg, 0.025
mmol), N-tosyl-2-(2-(ethynyl)phenyl)ethanamine (15) (150 mg, 0.50
mmol) and iodobenzene (5a) (0.07 mL, 0.62 mmol) were mixed in Et3N
(1.5 mL) and toluene (1.0 mL). The mixture was stirred for 24 h at 50°C.
The crude product was purified through column chromatography (SiO2,
CH2Cl2/acetone 49:1), obtaining 58 mg (yield 29%) of 21a as two
conformational isomers, s-trans and s-cis, in the molar ratio 67/33, 16 mg
(4-Chlorophenyl)(3-tosyl-2,3-dihydro-1H-benzo[d]azepin-4-
yl)methanone (21c). Following the general procedure, PdCl2(PPh3)2 (1.4
mg, 0.0020 mmol), N-tosyl-2-(2-(ethynyl)phenyl)ethanamine (15) (150
mg, 0.50 mmol) and 1-chloro-4-iodobenzene (5c) (148 mg, 0.62 mmol)
were mixed in Et3N (1.5 mL) and toluene (1.0 mL). The mixture was
stirred for 6 h at 110°C. The crude product was purified through column
chromatography (neutral Al2O3, n-pentane/AcOEt 4:1), obtaining 133 mg
(yield 61%) of 21c as two conformational isomers, s-trans and s-cis, in
the molar ratio 64/36. 1H-NMR (CDCl3), δ (ppm): 2.31 (CH3, s, 0.64H),
2.35 (CH3, s, 0.36H), 2.56 (CH2, t, J = 6.3 Hz, 1.28H), 2.87 (CH2, t, J =
6.0 Hz, 0.72H), 3.71 (CH2, t, J = 6.3 Hz, 1.28H), 3.74 (CH2, t, J = 6.0 Hz,
0.72H), 6.94-6.95 (Ar, m, 0.64H), 6.98-7.00 (Ar, m, 0.36H), 7.05 (=CH, s,
0.64H), 7.07-7.09 (Ar, m, 1.64H), 7.18-7.25 (Ar, m, 2.72H), 7.29 (=CH, s,
0.36H), 7.40 (Ar, d, J = 7.8 Hz, 0.72H), 7.44 (Ar, d, J = 8.4 Hz, 1.28H),
7.53 (Ar, d, J = 7.8 Hz, 1.28H), 7.67 (Ar, d, J = 7.8 Hz, 0.72H), 7.72-7.73
(Ar, m, 0.64H), 7.86-7.88 (Ar, m, 2H). 13C-NMR (CDCl3), δ (ppm): (26.11,
26.94), (28.79, 29.66), (44.47, 45.56), (116.66, 119.06), (124.38, 125.96),
(126.51, 126.96), 127.37 (2C), (128.40, 128.81) (2C), (129.14, 129.37),
(129.63, 129.88), 130.03 (4C), (130.39, 130.73), (134.92, 135.16),
(136.47, 136.52), (136.67, 137.18), (138.40, 139.27), (141.34, 143.86),
(144.26, 144.88), (190.12, 192.34).
(yield
8%)
of
4-methyl-N-(2-(3-oxo-3-phenylprop-1-yn-1-
yl)phenethyl)benzenesulfonamide (20) and 12 mg (yield 4%) of the side
product N,N'-((buta-1,3-diyne-1,4-diylbis(2,1-phenylene)) bis(ethane-2,1-
diyl))bis(4-methylbenzenesulfonamide) (22): 1H-NMR (CDCl3), δ (ppm):
2.38 (6H, s), 3.00-3.03 (4H, m), 3.25-3.28 (4H, m), 4.84 (2H, t, J = 6.0
Hz), 7.16 (2H, d, J = 7.8 Hz), 7.20-7.30 (8H, m), 7.50 (2H, d, J = 7.8 Hz),
7.72 (4H, d, J = 7.8 Hz). LC-MS APCI (+) [M+H]+: 597.4.
(4-Methoxyphenyl)(3-tosyl-2,3-dihydro-1H-benzo[d]azepin-4-
yl)methanone (21b). Following the general procedure, PdCl2(PPh3)2 (1.4
mg, 0.0020 mmol), N-tosyl-2-(2-(ethynyl)phenyl)ethanamine (15) (150
mg, 0.50 mmol) and 4-iodoanisole (5b) (145 mg, 0.62 mmol) were mixed
in Et3N (1.5 mL) and toluene (1.0 mL). The mixture was stirred for 6 h at
110°C. The crude product was purified through column chromatography
(neutral Al2O3, n-hexane/AcOEt 3:1), obtaining 140 mg (yield 65%) of
21b as two conformational isomers, s-trans and s-cis, in the molar ratio
50/50. 1H-NMR (CDCl3), δ (ppm): 2.29 (CH3, s, 1.5H), 2.32 (CH3, s,
1.5H), 2.62 (CH2, t, J = 6.0 Hz, 1H), 2.84 (CH2, t, J = 6.0 Hz, 1H), 3.72
(CH2, t, J = 6.0 Hz, 1H), 3.75 (CH2, t, J = 6.0 Hz, 1H), 3.87 (CH3, s,
1.5H), 3.88 (CH3, s, 1.5H), 6.92-6.98 (Ar, m, 3.5H), 7.01 (Ar, d, J = 7.2
Hz, 0.5H), 7.05-7.07 (Ar, m, 1H), 7.09 (=CH, s, 0.5H), 7.14-7.17 (Ar, m,
2.5H), 7.21-7.23 (Ar, m, 0.5H), 7.29 (=CH, s, 0.5H), 7.54 (Ar, d, J = 7.8
Hz, 0.5H), 7.65 (Ar, d, J = 7.8 Hz, 1H), 7.70-7.72 (Ar, m, 0.5H), 7.92 (Ar,
d, J = 7.8 Hz, 1H), 7.98 (Ar, d, J = 8.4 Hz, 1H). 13C-NMR (CDCl3), δ
(ppm): (21.42, 21.44), (26.32, 28.59), (44.63, 45.64), (55.39, 55.46),
(113.40, 113.79) (2C), (119.21, 120.04), (124.32, 125.92), (126.50,
126.81), (127.34, 127.50) (2C), (128.78, 129.14), (129.26, 129.53) (2C),
(130.91, 131.05) (2C), 131.52, (134.88, 135.30), (136.18, 136.64),
140.21, (142.70, 143.60), 143.99, (163.05, 163.57), (190.30, 191.71).
LC-MS APCI (+) [M+H]+: 434.3.
LC-MS APCI (+) [M+H]+: 438.2.
4-(3-tosyl-2,3-dihydro-1H-benzo[d]azepine-4-carbonyl)benzonitrile
(21d). Following the general procedure, PdCl2(PPh3)2 (1.4 mg, 0.0020
mmol), N-tosyl-2-(2-(ethynyl)phenyl)ethanamine (15) (150 mg, 0.50
mmol) and 4-iodobenzonitrile (5d) (142 mg, 0.62 mmol) were mixed in
Et3N (1.5 mL) and toluene (1.0 mL). The mixture was stirred for 6 h at
110°C. The crude product was purified through column chromatography
(neutral Al2O3, n-hexane/AcOEt 7:3), obtaining 135 mg (yield 63%) of
21d as two conformational isomers, s-trans and s-cis, in the molar ratio
78/22, 36 mg (yield 18%) of N-(2-((4-cyanophenyl)ethynyl)phenethyl)-4-
methylbenzenesulfonamide (23) and 12 mg (yield 9%) of 4-(2,3-dihydro-
1H-benzo[d]azepine-4-carbonyl)benzonitrile (24).
21d: 1H-NMR (CDCl3), δ (ppm): 2.30 (CH3, s, 2.34H), 2.36 (CH3, s,
0.66H), 2.48 (CH2, t, J = 6.0 Hz, 1.56H), 2.88 (CH2, t, J = 6.0 Hz, 0.44H),
3.64 (CH2, t, J = 6.0 Hz, 1.56H), 3.75 (CH2, t, J =
(2-Methoxyphenyl)(3-tosyl-2,3-dihydro-1H-benzo[d]azepin-4-
yl)methanone (21f). Following the general procedure, PdCl2(PPh3)2 (1.4
mg, 0.0020 mmol), N-tosyl-2-(2-(ethynyl)phenyl)ethanamine (15) (150
This article is protected by copyright. All rights reserved.